Grape King Bio Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	10yrs
Durata media del Consiglio di amministrazione	3.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

How Much Did Grape King Bio's(TPE:1707) Shareholders Earn From Share Price Movements Over The Last Year?

Feb 27

Grape King Bio (TPE:1707) Seems To Use Debt Quite Sensibly

Nov 20

AMMINISTRATORE DELEGATO

Grape King Bio non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Sheng-Lin Tseng	Chairman & GM	15.4yrs	Nessun dato	0.73% NT$ 167.4m
Nick Hung	Accounting Supervisor	10.8yrs	Nessun dato	Nessun dato
Bing-Jyun Cuei	Chief Legal Officer	3.3yrs	Nessun dato	Nessun dato

10.0yrs

Durata media

Gestione esperta: Il team dirigenziale di 1707 è esperto e expertise (durata media dell'incarico 10 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Sheng-Lin Tseng	Chairman & GM	15.4yrs	Nessun dato	0.73% NT$ 167.4m
Mei-Ching Tseng	Director	9.4yrs	Nessun dato	1.99% NT$ 454.9m
Jue-Jia Chang	Director	15.4yrs	Nessun dato	Nessun dato
Chih-Wei Lai	Director	6.5yrs	Nessun dato	0.44% NT$ 100.6m
Yen-Shiang Huang	Director	6.5yrs	Nessun dato	0.14% NT$ 31.3m
Hsing-Chun Chen	Director	3.3yrs	Nessun dato	1.08% NT$ 245.7m
Jing-Ning Chen	Independent Director	3.3yrs	Nessun dato	Nessun dato
Chi J. Yu	Independent Director	less than a year	Nessun dato	Nessun dato
Pang-Chung Chin	Independent Director	less than a year	Nessun dato	Nessun dato
Ting-Ju Chen	Independent Director	less than a year	Nessun dato	Nessun dato
Jia-Fong Chai	Representative Director	less than a year	Nessun dato	Nessun dato
Bang Jin	Independent Director	less than a year	Nessun dato	Nessun dato

3.3yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 1707 sono considerati esperti (durata media dell'incarico 3.3 anni).

Grape King Bio Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Grape King Bio Ltd Announces Changes to Remuneration Committee

Grape King Bio Ltd Approves Changes to the Board

Grape King Bio Ltd, Annual General Meeting, May 30, 2024

Less than half of directors are independent

Less than half of directors are independent

Grape King Bio Ltd, Annual General Meeting, May 27, 2022

Recent updates

Third quarter 2024 earnings released: EPS: NT$2.81 (vs NT$2.48 in 3Q 2023)

Grape King Bio Ltd to Report Q3, 2024 Results on Nov 11, 2024

Now 21% overvalued

Second quarter 2024 earnings: EPS misses analyst expectations

Grape King Bio Ltd Announces Changes to Remuneration Committee

Grape King Bio Ltd to Report Q2, 2024 Results on Aug 12, 2024

Grape King Bio's (TWSE:1707) Dividend Will Be NT$6.90

Upcoming dividend of NT$6.90 per share

Grape King Bio (TWSE:1707) Will Pay A Dividend Of NT$6.90

Dividend of NT$6.90 announced

Grape King Bio Ltd Approves Changes to the Board

Grape King Bio Ltd Announces Dividend, Payable on July 18, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Grape King Bio Ltd to Report Q1, 2024 Results on May 13, 2024

Full year 2023 earnings: EPS misses analyst expectations

Grape King Bio Ltd, Annual General Meeting, May 30, 2024

Price target decreased by 12% to NT$170

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Upcoming dividend of NT$6.90 per share at 3.9% yield

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 22% undervalued after recent price drop

Now 21% undervalued

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of NT$6.10 per share

Grape King Bio Ltd Announces Cash Dividend

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Now 20% undervalued after recent price drop

Full year 2021 earnings: EPS misses analyst expectations

Grape King Bio Ltd, Annual General Meeting, May 27, 2022

Grape King Bio Ltd Applies to FDA for A Phase II Clinical Trial Review in Humans for GKAC

Third quarter 2021 earnings released: EPS NT$2.04 (vs NT$2.23 in 3Q 2020)

Price target decreased to NT$195

Second quarter 2021 earnings released: EPS NT$2.20 (vs NT$2.09 in 2Q 2020)

Upcoming dividend of NT$6.40 per share

First quarter 2021 earnings released: EPS NT$1.60 (vs NT$1.93 in 1Q 2020)

First quarter 2021 earnings released: EPS NT$1.60 (vs NT$1.93 in 1Q 2020)

Grape King Bio (TPE:1707) Knows How To Allocate Capital

Here's Why Grape King Bio (TPE:1707) Can Manage Its Debt Responsibly

Grape King Bio's (TPE:1707) Anemic Earnings Might Be Worse Than You Think

Revenue beats expectations

How Much Did Grape King Bio's(TPE:1707) Shareholders Earn From Share Price Movements Over The Last Year?

Full year 2020 earnings released: EPS NT$9.34 (vs NT$9.63 in FY 2019)

Grape King Bio Ltd, Annual General Meeting, May 28, 2021

New 90-day high: NT$181

Grape King Bio Ltd announced that it expects to receive TWD 2.01467 billion in funding from Uni-President Enterprises Corp.

Grape King Bio (TPE:1707) Seems To Use Debt Quite Sensibly

Price target lowered to NT$206

Third quarter 2020 earnings released: EPS NT$2.23

Earnings beat expectations, revenue disappoints

New 90-day low: NT$167

New 90-day low: NT$176

New 90-day low - NT$178

New 90-day low - NT$184

First half earnings released

AMMINISTRATORE DELEGATO

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media